Pharmaceuticals

RINGPU

RINGPU released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 826.13 M, actual EPS CNY 0.2374

RINGPU to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

RINGPU released FY2025 Annual Earnings on March 30 After-Market BJT, actual revenue CNY 3.398 B (forecast CNY 3.599 B), actual EPS CNY 0.8815 (forecast CNY 1.0014)

RINGPU released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 854.13 M, actual EPS CNY 0.0841

RINGPU to Release FY2025 Annual Earnings on March 31 After-Market (BJT), Forecast Revenue CNY 3.599 B, EPS CNY 0.9866

RINGPU released FY2025 9 Months earnings on October 24 After-Market BJT, actual revenue CNY 2.544 B, actual EPS CNY 0.7972

RINGPU released FY2025 Q3 earnings on October 24 After-Market BJT, actual revenue CNY 836.74 M, actual EPS CNY 0.2329

RINGPU FY2025 Q3 Earnings Release on October 25, After-Market (BJT)

RINGPU released FY2025 Semi-Annual earnings on August 25 After-Market (BJT), actual revenue CNY 1.708 B (forecast CNY 1.661 B), actual EPS CNY 0.5642

RINGPU released FY2025 Q2 earnings on August 25 After-Market BJT, actual revenue CNY 885.97 M, actual EPS CNY 0.3093

RINGPU to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT), Forecast Revenue CNY 1.661 B

Ruipu Biotech Obtains Clinical Trial Approval for Swine Epidemic Diarrhea Virus mRNA Vaccine

Mingxin Securities Issues Buy Rating for Ruipu Bio

RipBio Expects Net Profit Growth of 50%-70% in First Half of 2025

RuiP Biopharmaceutical's Miao Pu Jing Listed, Cat Interferon to be Launched in H2

Ri Pu Bio's 参股 Ri Pai Pet Hospital covers 27 provinces

Ribi Biopharm Plans to Transfer Equity in Zhong'an Bio

RuiP Bio Inc. Engaged in Large Block Trading

Ri 普 Bio's stock price plummets, vaccine industry profit growth slows

RuiPu BioPharm Shares Rise, Multiple Securities Firms Issue Buy Ratings

300119

GenScript has officially opened its first European mRNA production site in Delft, Netherlands, enhancing its global mRNA platform and reinforcing Europe as a key part of its R&D and production network. This facility aims to improve collaboration, turnaround times, and regulatory alignment for European biotech innovators. The site offers comprehensive mRNA workflow capabilities and integrates with GenScript's global operations, reflecting the company's commitment to advancing biotechnology through strategic investments in resilient infrastructure.

prnewswire

02:49 ETGenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub

603392

600201

603566

300142

688185

06185

Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

Zhitong

Wantai Biological

JINYU

PULIKE

WALVAX

CanSinoBIO

CANSINOBIO

Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

RINGPU recently stated at an analyst meeting that the company has established a pilot production line for mycelium protein and completed the research on pilot production processes, possessing the foundation and conditions for industrialization and promotion. The new production facility has already begun construction. According to the feasibility study report, after the project is fully operational, the expected annual revenue will be 1.3 billion yuan

RINGPU: A pilot production line for mycelium protein has been established, providing a foundation for industrialization and promotion conditions

RINGPU stated at an analyst meeting that the company's "Double Eleven" pet-related work has been fully promoted: launching full-platform pre-sale preparations for shelf e-commerce on core channels such as Tmall and JD.com, and customizing exclusive peripheral gifts to reward consumers; cooperating with leading live streaming rooms, and will closely coordinate with the rhythm of the live streaming rooms to ensure adequate stock, logistics, and other backend support, fully enhancing the conversion effect of the live streaming rooms

RINGPU: "Double Eleven" pet-related work has been fully promoted

According to the Zhitong Finance APP, RINGPU released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.544 billion yuan, a year-on-year increase of 13.50%. The net profit attributable to shareholders of the listed company was 362 million yuan, a year-on-year increase of 45.64%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 269 million yuan, a year-on-year increase of 24.92%. The basic earnings per share were 0.7972 yuan

RINGPU released its performance for the first three quarters, with a net profit attributable to the parent company of 362 million yuan, an increase of 45.64%

RINGPU announced that its revenue for the third quarter was 837 million yuan, a year-on-year increase of 1.44%; net profit was 106 million yuan, a year-on-year increase of 23.02%. Revenue for the first three quarters was 2.544 billion yuan, a year-on-year increase of 13.50%; net profit was 362 million yuan, a year-on-year increase of 45.64%

RINGPU: The net profit for the third quarter was 106 million yuan, a year-on-year increase of 23.02%

According to the Zhitong Finance APP, RINGPU announced that the company plans to participate in the investment to establish Tianjin Baorui Equity Investment Partnership (Limited Partnership) (tentative name), aimed at investing in targets related to the pet industry chain. The total capital contribution of the partnership is 406 million yuan, of which the company, as a limited partner, will contribute 154 million yuan from its own funds

RINGPU plans to invest CNY 154 million to establish Tianjin Baorui, focusing on the pet industry chain-related targets

HuaChuang Securities released a research report indicating that since 2025, the prices of veterinary raw materials have stabilized and rebounded, especially for macrolide products, where prices and profits have significantly improved. From January to August, the batch issuance data for vaccines saw a substantial year-on-year increase, with pet vaccines such as rabies vaccine and feline trivalent vaccine growing by 16.8% and 78.9%, respectively. The prices of veterinary raw materials rebounded since late August, with the VPI index rising by approximately 2.1%. The tightening of supply and increased demand have driven price increases, particularly benefiting products like florfenicol as market competition eases

Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increases

RINGPU recently obtained a new veterinary drug registration certificate issued by the Ministry of Agriculture and Rural Affairs, involving a four-in-one inactivated vaccine for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and infectious bursal disease. This product fills a gap in the domestic market, demonstrating the company's innovative capabilities in the poultry vaccine field, further consolidating its market position, and will bring new performance growth points for the company

RINGPU obtained a new veterinary drug registration certificate

RINGPU announced that it released its 2025 semi-annual report, with operating revenue of 1.708 billion yuan, a year-on-year increase of 20.53%; the net profit attributable to shareholders of the listed company was 257 million yuan, a year-on-year increase of 57.59%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

RINGPU: Net profit in the first half of the year increased by 57.59% year-on-year

RINGPU(300119.SZ)